摘要
头颈部鳞状细胞癌是一类恶性程度较高的恶性肿瘤,全球每年约有90万新发病例和50万人因罹患头颈部鳞状细胞癌死亡。目前,肿瘤治疗指南中仍将铂类化疗药物联合靶向药物治疗作为头颈部鳞状细胞癌的一线治疗方案,虽然临床上提示有效,但患者中位总生存期只有6~9个月。如何缓解患者痛苦,延长患者的生存时间仍是亟待解决的难题。近年来,随着免疫治疗逐步发展,以PD-1/PD-L1为代表的免疫检查点抑制剂在晚期、复发的头颈部鳞状细胞癌临床治疗中取得了良好的治疗效果,为患者的治疗以及临床医师制订治疗方案提供了新的选择和思路。免疫检查点抑制剂治疗联合靶向治疗、放化疗的序贯问题仍在探索中,许多临床试验仍在进行当中,同时新型靶点的药物研发,如细胞治疗的新型治疗方法,也在进一步探索完全控制肿瘤的可能性。本文就头颈部鳞状细胞癌免疫治疗的进展与相关免疫检查点抑制剂研究进展进行综述,以期为头颈部鳞状细胞癌的临床治疗提供参考。
Head and neck squamous cell carcinoma is a type of malignant tumor with a high degree of malignancy.Every year,about 900000 new cases and 500000 people die from head and neck squamous cell carcinoma in the world.At present,platinum chemotherapeutic drugs combined with targeted drugs are still used as the first-line treatment plan in the cancer treatment guidelines.Although clinically effective,the median survival time of patients is only 6-9 months.How to relieve patients'pain and prolong their survival time are still the difficult problems.In recent years,with the gradual development of immunotherapy,immune checkpoint inhibitors represented by PD-1/PD-L1 have achieved good therapeutic effects in the clinical treatment of advanced and recurrent head and neck squamous cell carcinoma,which provides new options and ideas for patients'treatment and clinicans to formulate treatment plans.The sequential problem of immune checkpoint inhibitors combined with targeted therapy,radiotherapy and chemotherapy is still being explored,and many clinical trials are still in progress.At the same time,drug research and development of new targets,such as new therapeutic methods of cell therapy,are also further exploring the possibility of completely controlling tumors.This article reviews the progress of immunotherapy and the research progress of related immune checkpoint inhibitors for head and neck squamous cell carcinoma,in order to provide reference for the clinical treatment of head and neck squamous cell carcinoma.
作者
孙立伟
李林
李金铎
刘晓民
SUN Li-wei;LI Lin;LI Jin-duo;LIU Xiao-min(Head and Neck(Nerve)Tumor Center,Tianjin Huanhu Hospital,Tianjin 300350,China)
出处
《中国城乡企业卫生》
2023年第7期47-50,共4页
Chinese Journal of Urban and Rural Enterprise Hygiene
